Bristol Myers Squibb has the first positive phase 3 results under its belt for mezigdomide, a second experimental drug in its much-trumpeted celmod development programme for multiple myeloma. Interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results